SANOFI ADR

NASDAQ: SNY (Sanofi)

最近更新时间: 05 Jul, 12:00AM

48.30

-1.01 (-2.05%)

前收盘价格 49.31
收盘价格 48.70
成交量 1,555,600
平均成交量 (3个月) 2,654,747
市值 118,483,279,872
市盈率 (P/E TTM) 16.37
预期市盈率 (P/E Forward) 10.05
价格/销量 (P/S) 2.28
股市价格/股市净资产 (P/B) 1.35
52周波幅
45.80 (-5%) — 60.12 (24%)
利润日期 31 Jul 2025
股息率 (DY TTM) 4.58%
营业毛利率 13.95%
营业利益率 (TTM) 20.78%
稀释每股收益 (EPS TTM) 2.92
季度收入增长率 (YOY) -4.60%
季度盈利增长率 (YOY) 65.20%
总债务/股东权益 (D/E MRQ) 23.01%
流动比率 (MRQ) 1.46
营业现金流 (OCF TTM) 9.08 B
杠杆自由现金流 (LFCF TTM) -4.94 B
资产报酬率 (ROA TTM) 4.28%
股东权益报酬率 (ROE TTM) 7.30%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 混合的
Drug Manufacturers - General (全球的) 混合的 混合的
股票 Sanofi 混合的 看涨

AIStockmoo 评分

1.0
分析师共识 NA
内部交易活动 NA
价格波动 1.5
技术平均移动指标 3.5
技术振荡指标 -2.0
平均 1.00

相关股票

股票 市值 DY P/E(TTM) P/B
SNY 118 B 4.58% 16.37 1.35
AZN 226 B 2.13% 29.27 5.37
AMGN 160 B 3.11% 27.16 25.34
GILD 136 B 2.85% 23.03 7.26
GRFS 6 B - 28.00 0.960
BIIB 20 B - 13.29 1.16

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Core
机构持股比例 10.48%

该时间范围内无数据。

该时间范围内无数据。

日期 类型 细节
18 Jul 2025 公告 Press Release: Sanofi completes acquisition of Blueprint Medicines
18 Jul 2025 公告 Press Release: Sanofi completes acquisition of Blueprint Medicines
17 Jul 2025 公告 Press Release: Sanofi announces extension of Blueprint tender offer
17 Jul 2025 公告 Press Release: Sanofi announces extension of Blueprint tender offer
16 Jul 2025 公告 Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
16 Jul 2025 公告 Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
09 Jul 2025 公告 Sanofi: Information concerning the total number of voting rights and shares - June 2025
01 Jul 2025 公告 Adagene announces up to $25 million strategic investment from Sanofi
30 Jun 2025 公告 Press release: Availability of the Q2 2025 Aide mémoire
30 Jun 2025 公告 Press release: Availability of the Q2 2025 Aide mémoire
30 Jun 2025 公告 Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
30 Jun 2025 公告 Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
26 Jun 2025 公告 Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
26 Jun 2025 CNBC RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants
25 Jun 2025 公告 Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
25 Jun 2025 公告 Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
23 Jun 2025 公告 Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
23 Jun 2025 公告 Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
20 Jun 2025 公告 Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
20 Jun 2025 公告 Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
18 Jun 2025 CNBC RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
17 Jun 2025 公告 Press release: Sanofi successfully prices €1.5 billion bond issue
17 Jun 2025 公告 Press release: Sanofi successfully prices €1.5 billion bond issue
15 Jun 2025 公告 Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
15 Jun 2025 公告 Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
09 Jun 2025 CNBC FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
09 Jun 2025 公告 Sanofi: Information concerning the total number of voting rights and shares - May 2025
09 Jun 2025 公告 Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
09 Jun 2025 公告 Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
05 Jun 2025 公告 Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
03 Jun 2025 公告 Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
03 Jun 2025 公告 Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
03 Jun 2025 公告 Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
03 Jun 2025 公告 Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
02 Jun 2025 公告 Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
02 Jun 2025 公告 Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
02 Jun 2025 公告 Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
30 May 2025 公告 Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
30 May 2025 公告 Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
29 May 2025 公告 Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
29 May 2025 公告 Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
22 May 2025 公告 Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
21 May 2025 公告 Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
21 May 2025 公告 Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
21 May 2025 公告 Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
20 May 2025 公告 Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)
15 May 2025 公告 Sanofi: Information concerning the total number of voting rights and shares - April 2025
14 May 2025 公告 Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
02 May 2025 公告 Sanofi: Information concerning the total number of voting rights and shares - March 2025
30 Apr 2025 公告 Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
30 Apr 2025 公告 Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
30 Apr 2025 公告 Press Release: Annual General Meeting of April 30, 2025
30 Apr 2025 公告 Press Release: Annual General Meeting of April 30, 2025
29 Apr 2025 公告 Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
29 Apr 2025 公告 Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
24 Apr 2025 公告 Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
24 Apr 2025 公告 Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
显示更多
股息率 (DY TTM) 4.58%
5年平均股息收益率 4.78%
股息支付比率 75.37%
预计下次股息支付 Jun 2026
除息日 公告日期 支付日期 详情
09 May 2025 15 Apr 2025 12 Jun 2025 2.212154 现金
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 现金
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 现金
30 May 2023 - 23 Jun 2023 1.9000852 现金
26 May 2022 - 27 Jun 2022 0.2971788 现金
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 现金
03 May 2021 23 Mar 2021 26 May 2021 1.906064 现金
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 现金
07 May 2019 - 31 May 2019 1.722322 现金
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 现金
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 现金
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 现金
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 现金
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 现金
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 现金
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 现金
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 2.21 1 4.58
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票